WO2014108918A3 - Injectable antifungal formulation - Google Patents
Injectable antifungal formulation Download PDFInfo
- Publication number
- WO2014108918A3 WO2014108918A3 PCT/IN2014/000016 IN2014000016W WO2014108918A3 WO 2014108918 A3 WO2014108918 A3 WO 2014108918A3 IN 2014000016 W IN2014000016 W IN 2014000016W WO 2014108918 A3 WO2014108918 A3 WO 2014108918A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antifungal formulation
- injectable
- formulation
- injectable antifungal
- reconstitution
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
- 229960004740 voriconazole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN120CH2013 | 2013-01-08 | ||
| IN120/CHE/2013 | 2013-01-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2014108918A2 WO2014108918A2 (en) | 2014-07-17 |
| WO2014108918A3 true WO2014108918A3 (en) | 2014-12-04 |
Family
ID=51167477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2014/000016 WO2014108918A2 (en) | 2013-01-08 | 2014-01-07 | An injectable antifungal formulation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014108918A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106902358B (zh) * | 2015-12-21 | 2020-07-10 | 广州市香雪制药股份有限公司 | 口服制剂及其制备方法 |
| CN106902357B (zh) * | 2015-12-21 | 2021-08-03 | 广州市香雪制药股份有限公司 | 药物组合物及其应用、药物包合物、静脉制剂及制备方法 |
| UY38431A (es) * | 2018-10-31 | 2020-05-29 | Servier Lab | Formulación basada en ciclodextrina de un inhibidor de bcl-2 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788725A (zh) * | 2004-12-15 | 2006-06-21 | 北京博尔达生物技术开发有限公司 | 注射用伏立康唑冻干粉针剂及其制备方法 |
| EP2018866A1 (de) * | 2007-07-27 | 2009-01-28 | Sandoz AG | Pharmazeutische Zusammensetzungen mit Voriconazol |
| EP2409699A1 (de) * | 2010-07-23 | 2012-01-25 | Combino Pharm, S.L. | Stabile Voriconazole-enthaltende Zusammensetzungen |
| WO2012171561A1 (en) * | 2011-06-15 | 2012-12-20 | Synthon Bv | Stabilized voriconazole composition |
-
2014
- 2014-01-07 WO PCT/IN2014/000016 patent/WO2014108918A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788725A (zh) * | 2004-12-15 | 2006-06-21 | 北京博尔达生物技术开发有限公司 | 注射用伏立康唑冻干粉针剂及其制备方法 |
| EP2018866A1 (de) * | 2007-07-27 | 2009-01-28 | Sandoz AG | Pharmazeutische Zusammensetzungen mit Voriconazol |
| EP2409699A1 (de) * | 2010-07-23 | 2012-01-25 | Combino Pharm, S.L. | Stabile Voriconazole-enthaltende Zusammensetzungen |
| WO2012171561A1 (en) * | 2011-06-15 | 2012-12-20 | Synthon Bv | Stabilized voriconazole composition |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014108918A2 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015081257A3 (en) | Aminopyridine derivatives as tam family kinase inhibitors | |
| EP3060229A4 (de) | Stabile wässrige antikörperformulierungen | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| PH12015502178A1 (en) | Pyridinylpyrazoloquinoline compound | |
| EP3073171A4 (de) | Wärmeisolierungsschicht und wärmeisolierungsschichtstruktur | |
| WO2012162414A3 (en) | Shirt collar stabilizer | |
| EP3068269A4 (de) | Schlafsack mit selbstverschliessendem und belüftetem fussfach | |
| HUE062561T2 (hu) | Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai | |
| WO2015173427A3 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique | |
| HUP1300647A2 (hu) | Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik | |
| PL3090042T3 (pl) | Szczepy drożdży do wytwarzania etanolu pierwszej generacji | |
| IL233055A (en) | History of (1r, r4) 7 – oxo – 2 – azabicyclo [2.2.2] oct – 5 – ann | |
| PH12016500847A1 (en) | Multi-particulate drug delivery system | |
| WO2014108918A3 (en) | Injectable antifungal formulation | |
| SI3226905T1 (sl) | Konjugati hialuronana s farmacevtskimi učinkovinami, postopki in sestavki | |
| WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
| WO2014166836A8 (en) | Growth hormone compound formulation | |
| WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
| PH12014501384A1 (en) | Antibiotic formulations | |
| WO2012104874A3 (en) | Aqueous concentrated formulation of linezolid | |
| EP3090736A4 (de) | Wässrige zusammensetzung für hartkapsel und damit hergestellte hartkapsel | |
| EP3090735A4 (de) | Wässrige zusammensetzung für hartkapsel und damit hergestellte hartkapsel | |
| 李超 | Auto Term Translation: a Problem-solution Approach | |
| HK40014126A (en) | Single-dose, ready-to-use injectable formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14737827 Country of ref document: EP Kind code of ref document: A2 |